Published January 1986
by Thieme Medical Pub .
Written in English
|The Physical Object|
Download Citation | On Jan 1, , Jeremy L. Ockrim MD, BSc, FRCS and others published Treatment Options in Superficial (pTA/pT1/CIS) Bladder Cancer | Find, read and cite all the research you. It is estimated that there were approximat prevalent cases (15, males and females) of bladder carcinoma in Japan in 1 Based on the data available for the period from through , cases of superficial bladder carcinoma accounted for ≈60% of the total cases of bladder carcinoma. 2 In the United States, it has been estimated that there w prevalent Cited by: Abstract. We assigned 55 patients with superficial transitional cell carcinoma of the bladder by rotation to 1 of 3 treatment categories. Group 1 patients were treated by transurethral resection alone, group 2 by transurethral resection followed by topical thiotepa and group 3 by transurethral resection followed by orally administered bacillus by: Esposti PL, Tribukait B and Gustafson H. Effect of local treatment with adriamycin in carcinoma in situ of the urinary bladder: cell morphology and DNA analysis for quantification of malignant cells. In: Diagnostics and treatment of superficial bladder tumors. WHO collaborating centre for research and treatment of urinary bladder cancer.
Purpose: To determine maximum-tolerated dose, toxicities, and pharmacokinetics associated with weekly intravesical gemcitabine therapy in patients with superficial bladder cancer. Patients and Methods: Fifteen patients with recurrent superficial transitional cell bladder carcinoma who experienced prior intravesical therapy failure were studied. Two to 4 weeks after complete . Intravesical therapy has been used in the management of superficial transitional cell carcinoma (TCC) of the urinary bladder (Ie, Ta, Tl, and carcinoma in situ [CIS]) with specific objectives that include treating existing/residual tumor, preventing recurrence of tumor, preventing disease progression, and prolonging survival. Additional trials will be necessary in prophylactic as well as definitive therapy of superficial bladder cancer to evaluate fully this therapeutic modality. REFERENCES 1. Soloway, M. S.: The management of superficial bladder cancer. Cancer, , 2. ON THIS PAGE: You will learn about the general types of treatments doctors use to treat people with bladder cancer based on the stage of the disease. Use the menu to see other information below outlines common types of treatment that may be part of your treatment plan, depending on the cancer’s stage (see Stages and Grades). Please note that your doctor will.
Adolphs HD, Bastian HP: Chemoimmune prophylaxis of superficial bladder tumors. Results after treatment of more than patients in four years. Abstract Americal urological association, seventy-eight annual meeting, Las Vegas, Nevada, April, Google Scholar. Veenema RJ, Dean AL, Jr, Uson AC, Roberts M, Longo F. Thiotepa bladder instillations: therapy and prophylaxis for superficial bladder tumors. J Urol. May; (5)– Drew JE, Marshall VF. The effects of topical THIOTEPA on the recurrence rate of superficial bladder cancers. J Urol. Jun; 99 (6)– Superficial bladder cancer means it started in the lining of the bladder and hasn’t spread beyond it. Another name for it is non-muscle-invasive bladder cancer. Garnick M.B., Maxwell B., Gibbs R.S., Richie J.P. () Intravesical Doxorubicin for Prophylaxis in the Management of Recurrent Superficial Bladder Carcinoma — An Update. In: Howell S.B. (eds) Intra-Arterial and Intracavitary Cancer Chemotherapy.